Aldeyra Therapeutics, Inc. Class Action Lawsuit - ALDX

The filed complaint alleges that Aldeyra Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: On April 3, 2025, The company disclosed that the FDA issued a second Complete Response Letter (CRL) for reproxalap, Aldeyra's lead dry eye disease drug candidate. The FDA's CRL cited a failure to demonstrate efficacy for reproxalap and flagged concerns with the design of Aldeyra’s most recent trial, including differences in baseline symptom scores that may have impacted the reliability of their trial results. Following this news, shares of Aldeyra Therapeutics, Inc. fell over 74% in intraday trading.

In order to be eligible to join the ALDX class action lawsuit, you must have incurred a loss on shares of Aldeyra Therapeutics, Inc. purchased during the class period listed above.